Neos Therapeutics Receives U.S. FDA Approval of Adzenys ER™ (amphetamine) Extended-Release Oral Suspension for the Treatment of ADHD in Patients 6 Years and Older
15 sept. 2017 16h39 HE
|
Neos Therapeutics, Inc
DALLAS and FORT WORTH, Texas, Sept. 15, 2017 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq:NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing innovative...
Adamas Announces FDA Approval of GOCOVRI™ as First and Only Medication for the Treatment of Dyskinesia in Parkinson’s Disease Patients
24 août 2017 16h16 HE
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., Aug. 24, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that the U.S. Food and Drug Administration (FDA) has approved GOCOVRI (amantadine)...
Adamas Reports Recent Achievements and Second Quarter 2017 Financial Results
08 août 2017 16h01 HE
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., Aug. 08, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today reported recent achievements and financial results for the second quarter ended June 30, 2017. ...
Adamas to Announce Second Quarter 2017 Financial Results and Host Conference Call on August 8, 2017
01 août 2017 14h33 HE
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., Aug. 01, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that the company will report second quarter 2017 financial results on Tuesday, August...
Adamas Appoints New Chief Financial Officer
28 juin 2017 09h00 HE
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif, June 28, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced the appointment of Alfred G. Merriweather as Chief Financial Officer, reporting to...
Neos Therapeutics Announces FDA Approval of Cotempla XR-ODT™ (methylphenidate) Extended-Release Orally Disintegrating Tablets for the Treatment of ADHD in Patients 6 to 17 Years Old
19 juin 2017 21h46 HE
|
Neos Therapeutics, Inc
DALLAS and FORT WORTH, Texas, June 19, 2017 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq:NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing innovative...
Adamas Announces Publication of ADS-5102 Phase 3 EASE LID Clinical Trial in JAMA Neurology
12 juin 2017 16h01 HE
|
Adamas Pharmaceuticals, Inc.
--Placebo-Controlled Phase 3 Trial Demonstrated that ADS-5102 Significantly Reduced Both Dyskinesia and OFF Time at Six Months in Parkinson’s Disease Patients with Levodopa-induced Dyskinesia -- --...
Adamas Presents Expanded Analysis from the ADS-5102 Open-Label Study Showing Tolerability and Durability out to 88 Weeks
08 juin 2017 16h10 HE
|
Adamas Pharmaceuticals, Inc.
-- New subgroup analyses showed that patients previously treated with amantadine IR received benefit of ADS-5102 comparable to patients previously treated with placebo -- -- New Drug Application...
Adamas Signs $100 Million Royalty-Backed Note Agreement with HealthCare Royalty Partners
11 mai 2017 09h11 HE
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., May 11, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that it has entered into a $100 million royalty-backed note agreement with HealthCare...
Adamas Reports Recent Achievements and First Quarter 2017 Financial Results
09 mai 2017 16h01 HE
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., May 09, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today reported recent achievements and financial results for the first quarter ended March 31, 2017. ...